M
Memo Therapeutics
An innovator in the field of antibody discovery and immune repertoire analysis
About Memo Therapeutics
Memo Therapeutics is a biopharmaceutical company specializing in developing innovative treatments for complex diseases through its cutting-edge therapeutic platform. Based on their proprietary technology, Memo Therapeutics focuses on designing highly selective and effective treatments by targeting specific disease mechanisms at the molecular level.
The company's core platform utilizes advanced computational and experimental methods to identify and validate novel therapeutic targets. Memo Therapeutics aims to address unmet medical needs by creating precise and tailored therapies that can improve patient outcomes in challenging areas such as oncology, autoimmune diseases, and neurodegenerative disorders.
Memo Therapeutics' approach combines deep scientific expertise with a commitment to translating discoveries into actionable therapies. Their pipeline includes several promising candidates that are undergoing rigorous preclinical and clinical evaluations. By leveraging state-of-the-art technology and a multidisciplinary team, Memo Therapeutics strives to bring transformative medicines to market, ultimately enhancing the quality of life for patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 45
- Open positions
- None listed
- Dealroom signal
- 74.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2026 | $220M | $770M | Ipsen | ↗ |
| SERIES COther financing | May 2024 | $18M | $115M | Ysios Capital · Redalpine · Vesalius Biocapital Partners · Pureos Bioventures | ↗ |
Growth signals
Latest recorded traffic for Memo Therapeutics is 4.5K monthly website visits, up 55.2% over the last three months. Memo Therapeutics's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Memo Therapeutics in the Schlieren ecosystem
The Memo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
EVA Basel
Redalpine
ZKB - Zürcher Kantonalbank
Swisscanto Invest
Verve Ventures
Schroder Adveq- JPJaquet Partners
- BBBERNINA BioInvest
Vesalius Biocapital Partners
Adjuvant Capital
Fresenius Medical Care Ventures- GHGF Group Holding
Series B and later4 investors entered at this stage
Schroders Capital
Pureos Bioventures
Ysios Capital
Kurma Partners
Other known investors2 additional known investors
ETH Zurich
Ipsen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Memo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Memo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










